# The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

> **NCT06378580** · — · COMPLETED · sponsor: **Luo Cong** · enrollment: 72 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Surufatinib combine immune checkpoint inhibitor
- **DRUG:** AG/FOLFIRINOX

## Key facts

- **NCT ID:** NCT06378580
- **Lead sponsor:** Luo Cong
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378580, "The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06378580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*